“Efficacy of Halobetasol 0.01% Tazarotene 0.045% (HP TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP TAZ and Oral Treatment (Apremilast)”. SKIN The Journal of Cutaneous Medicine 3 (November 9, 2019): S30. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/757.